Sugi Predict

Sugi Predict / Compounds / SCHEMBL583415

SCHEMBL583415

SCHEMBL583415

CC(C)(C)OC(=O)C1CCCN1S(N)(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 2/20 0.48
▸ HSD17B10 Q99714 1/20 0.39
▸ CA2 P00918 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ EPHX1 P07099 1/20 0.33
▸ MMP1 P03956 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP13 P45452 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23897220 0.85 CASP3 (0.49) CASP3HSD17B10MEN1KMT2AHRH3
SCHEMBL7338741 0.81 CASP3 (0.45) CASP3CA2KMT2ASMN1; SMN2MMP13
SCHEMBL9131956 0.81 CASP3 (0.45) CASP3CA2KMT2ASMN1; SMN2MMP13
SCHEMBL10552578 0.80 CASP3 (0.46) CASP3HSD17B10MEN1KMT2AHRH3
SCHEMBL3898404 0.78 HSD17B10 (0.41) CASP3HSD17B10CA2MEN1KMT2A
SCHEMBL23999544 0.78 HSD17B10 (0.41) CASP3HSD17B10CA2MEN1KMT2A
SCHEMBL11601463 0.77 CASP3 (0.43) CASP3HSD17B10MEN1KMT2AHRH3
SCHEMBL20418353 0.77 CASP3 (0.51) CASP3MEN1KMT2AMMP1MMP9
SCHEMBL7332760 0.77 FKBP1A (0.44) CASP3MEN1KMT2ASMN1; SMN2MMP1
SCHEMBL7362291 0.76 HSD17B10 (0.42) CASP3HSD17B10CA2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2624826-B1 VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS NOVARTIS AG (CH) 2018-07-18 — — EP disclosed
CN-103179966-B Vitamin E formulations of sulfonamide NS3 inhibitors 诺瓦提斯公司 2017-03-15 — — CN disclosed
EP-2417108-B1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2016-08-17 — — EP disclosed
US-9206232-B2 Organic compounds and their uses NOVARTIS AG (CH) 2015-12-08 — — US disclosed
US-9011833-B2 Vitamin E formulations of sulfamide NS3 inhibitors NOVARTIS AG (CH) 2015-04-21 — — US disclosed
US-20140357551-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2014-12-04 — — US disclosed
US-8840878-B2 Peptidomimetic sulfamide compounds and antiviral uses thereof NOVARTIS AG (CH) 2014-09-23 — — US disclosed
US-8613914-B2 Peptidomimetic sulfamide compounds and antiviral uses thereof NOVARTIS AG (CH) 2013-12-24 — — US disclosed
US-20130338061-A1 Salts and Polymorphs of Sulfamide NS3 Inhibitors NOVARTIS AG (CH) 2013-12-19 — — US disclosed
US-8512690-B2 Derivatised proline containing peptide compounds as protease inhibitors NOVARTIS AG (CH) 2013-08-20 — — US disclosed
EP-2625167-A1 SALTS AND POLYMORPHS OF SULFAMIDE NS3 INHIBITORS Novartis AG (CH) 2013-08-14 — — EP disclosed
US-20130190229-A1 VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2013-07-25 — — US disclosed
CN-103179966-A Vitamin E formulations of sulfonamide NS3 inhibitors NOVARTIS AG 2013-06-26 — — CN disclosed
US-20130034519-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2013-02-07 — — US disclosed
US-20130022572-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2013-01-24 — — US disclosed
WO-2012048235-A1 VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS NOVARTIS AG (CH) 2012-04-12 — — WO disclosed
WO-2012045280-A1 SALTS AND POLYMORPHS OF SULFAMIDE NS3 INHIBITORS NOVARTIS AG (CH) 2012-04-12 — — WO disclosed
EP-2417108-A1 ORGANIC COMPOUNDS AND THEIR USES Novartis AG (CH) 2012-02-15 — — EP disclosed
WO-2010116248-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-10-14 — — WO disclosed
US-20100260709-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022572-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 CASP3 426/4885HSD17B10 465/4885CA2 1716/4885
US-20100260709-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 CASP3 426/4885HSD17B10 465/4885CA2 1716/4885
US-20130034519-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 CASP3 426/4885HSD17B10 465/4885CA2 1716/4885
US-20130190229-A1 VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS TTPA, SULT1E1, SQOR CASP3 2744/4885HSD17B10 487/4885CA2 4489/4885
US-20130338061-A1 Salts and Polymorphs of Sulfamide NS3 Inhibitors DPP8, DPP7, PRSS1 CASP3 838/4885HSD17B10 2054/4885CA2 1528/4885
US-20140357551-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 CASP3 775/4885HSD17B10 303/4885CA2 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.